Branded

Novartis gains FDA approval for a new indication for Kisqali
Novartis has received the Food and Drug Administration’s blessing for Kisqali (ribociclib) for women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
FDA approves Tpoxx, the first drug to treat smallpox
The Food and Drug Administration has given the green light for Siga Technologies’ Tpoxx (tecovirimat), the first drug with an indication for the treatment of smallpox.

Pfizer to reorganize into 3 business divisions

Pfizer is organizing itself into three different businesses: innovative medicines, consumer healthcare, and an established medicines division.
Inovio’s MERS vaccine yields positive results in Phase 1 study

Inovio’s MERS vaccine generated high levels of antibodies and induced broad-based T cell responses in Phase 1 study.
Merz's Xeomin for adults gets FDA approval

Merz North America has received the green light from the Food and Drug Administration for Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea, or excessive drooling, in adult patients.
Two senators urge GSK to end Shingrix shingles vaccine shortage

Although GlaxoSmithKline said it has developed a “fair and equitable” process to ship Shingrix, its new shingles vaccine, two U.S. senators are urging the drugmaker do more to boost inventory levels in the wake of a shortage.
Catalent acquires Juniper Pharmaceuticals

Catalent, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, is acquiring Juniper Pharmaceuticals.
Medisca, FlavoRx partner on product roll out in Canada

Medisca's collaboration with FlavoRx will bring better tasting prescription medicines to children and pets in Canada.
Florida's drug price transparency law takes effect

Pharmacists in Florida can now share cost information with patients, thanks to a new law that took effect July 1.
FDA clears CBD-based epilepsy drug Epidiolex

Epidiolex (cannabidiol, or CBD, oral solution) is indicated to treat two rare forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients 2 years old and older.

Novartis gains FDA approval for a new indication for Kisqali

FDA approves Tpoxx, the first drug to treat smallpox

Pfizer to reorganize into 3 business divisions

Inovio’s MERS vaccine yields positive results in Phase 1 study

Merz's Xeomin for adults gets FDA approval

Two senators urge GSK to end Shingrix shingles vaccine shortage

Catalent acquires Juniper Pharmaceuticals

Medisca, FlavoRx partner on product roll out in Canada

Florida's drug price transparency law takes effect

FDA clears CBD-based epilepsy drug Epidiolex